Calif. doctor, minister who promised herbal cancer cure to faithful arrested on fraud charges

Source: HealthNews Author: Greg Risling Calif. doc who hailed herbal cancer cure arrested LOS ANGELES — Dr. Christine Daniel promised to her patients what many considered the improbable — the chance to cure cancer through an herbal treatment. Using her influence as an ordained Pentecostal minister, Daniel tapped into the vessel of faith to entice people from across the nation to try her regimen. She even appeared on cable’s Trinity Broadcasting Network in December 2002 touting her cancer cure and its 60 percent success rate, according to federal investigators. Daniel, 55, of Los Angeles was arrested and charged Thursday with two counts each of wire and mail fraud and faces up to 80 years in prison if convicted. She is scheduled to appear in federal court Friday. A phone message left for Daniel’s attorney, Manuel Miller, was not immediately returned. Daniel was interviewed by investigators in August 2004, and she denied ever practicing alternative medicine for cancer, court documents show. She also attested that she never talked about a 60 percent cancer cure rate on television. In court documents, authorities contend Daniel took advantage of terminally ill cancer patients in their darkest hours, some of whom desperately sought alternative measures after enduring draining rounds of chemotherapy and radiation. In all, federal prosecutors said Daniel siphoned about $1.1 million from 55 families between 2001 and 2004. Six patients ranging in age from 4 to 69 died within seven months after seeing Daniel. One of those was Margaret Antwi, who traveled from [...]

2009-10-26T11:38:35-07:00October, 2009|Oral Cancer News|

Conducting oral examinations for cancer in general practice: what are the barriers?

Source: Family Practice Advance Access published online on October 15, 2009 Authors: J Wade et al. Background: The incidence of oral (mouth) cancer in the UK is continuing to rise. Individuals who are at greatest risk rarely visit a dentist but do consult general medical practitioners (GMPs). Therefore, GMPs could have an important role in the early detection of oral cancer. Research has shown that GMPs do not opportunistically screen high-risk individuals; however, the barriers to screening are poorly understood. Objectives: To understand the reasons why GMPs may not screen for oral cancer. Methods: A questionnaire was developed, using the Theory of Planned Behaviour (TPB), to measure GMPs attitudes to and screening for oral cancer. The questionnaire was designed using all the key theoretical constructs of the TPB and incorporating the themes identified in a qualitative elicitation study. The questionnaire was posted to 499 GPs in Surrey Primary Care trust. Results: Two hundred and twenty-eight completed questionnaires were returned (46%). Two TPB constructs [subjective norm (e.g. peer pressure) and perceived external control factors (e.g. adequate equipment, time constraints)] were identified as significant predictors of ‘intention’ to perform oral screening. Intention and perceived internal control factors (e.g. self-efficacy) were predictive of actually performing oral screening with patients. Conclusions: The results of the study suggest that there is considerable potential for improving intention to perform oral cancer screening in general practice. Theory-based interventions could include further training to enhance confidence, expertise, knowledge and ease of examination, the provision of adequate equipment in [...]

Dietary vitamin D and cancers of the oral cavity and esophagus

Source: Annals of Oncology 2009 20(9):1576-1581 Authors: L. Lipworth et al. Background: Data on the association between vitamin D and upper digestive tract neoplasms are limited. Methods: In two case–control studies in Italy, we examined the relation between dietary vitamin D intake and squamous cell carcinoma of the esophagus (SCCE; 304 cases) and oral/pharyngeal cancer (804 cases). Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by multiple logistic regression. Results: Adjusted ORs for SCCE and oral/pharyngeal cancer were 0.58 (95% CI 0.39–0.86) and 0.76 (95% CI 0.60–0.94), respectively, for the highest tertile of vitamin D intake. Using a reference group of those in the highest tertile of vitamin D who were never/former smokers, ORs were 8.7 (95% CI 4.1–18.7) for SCCE and 10.4 (95% CI 6.9–15.5) for oral/pharyngeal cancer among heavy smokers in the lowest vitamin D tertile; similarly, compared with those in the highest tertile of vitamin D who drank <3 alcoholic drinks/day, corresponding ORs were 41.9 (95% CI 13.7–128.6) for SCCE and 8.5 (95% CI 5.7–12.5) for oral/pharyngeal cancer, among heavy alcohol drinkers in the lowest vitamin D tertile. Conclusion: We observed inverse associations between dietary vitamin D intake and risk of SCCE and, perhaps, oral/pharyngeal cancer, which were most pronounced among heavy current smokers and heavy consumers of alcohol. Authors: L. Lipworth1,2, M. Rossi3, J. K. McLaughlin1,4, E. Negri3, R. Talamini5, F. Levi6, S. Franceschi7 and C. La Vecchia3,4,8 Authors' affiliations: 1 International Epidemiology Institute, Rockville, MD 2 Department of Preventive Medicine, Vanderbilt University Medical [...]

Snuff and chewing tobacco linked to increased risk of fatal MI or stroke

Source: WebMD Author: Marlene Busko Lyon, France - Smokeless tobacco—such as snuff and chewing tobacco—is not harmless when it comes to heart health, according to a new meta-analysis [1]. A review of 11 studies from Sweden and the US, almost entirely in men, showed that smokeless-tobacco users had an increased risk of death from MI or stroke. The study, by researchers at the International Agency for Research on Cancer(IARC), is published online August 18, 2009 in BMJ. Contrary to common belief that smokeless tobacco has very little effect on health, these products have been shown to increase cancer risk, coauthor and IARC researcher Dr Kurt Straif (Lyon, France) told heartwire. "There is sufficient evidence for a causal association between smokeless tobacco and oral and pancreatic cancer [2] and probably also esophageal cancer [3]," he said. "Now, this study adds evidence that smokeless tobacco causes death from cardiovascular diseases," Straif summarized. Widespread, growing use of snus Types of smokeless tobacco used in North America and Europe include dry snuff that is inhaled, as well as moist snuff (called snus in Sweden) and chewing tobacco (or spit tobacco), which are sucked inside the cheek. These products have been around for centuries, and after a decline in consumption for most of the 20th century, use has rebounded in the past few decades, the authors write. In 2000, 23.9% of men and 4.1% of women in Sweden reported using snus daily or occasionally. In the same year, in the US, 4.4% of men and 0.3% of women were [...]

2009-08-19T12:14:50-07:00August, 2009|Oral Cancer News|

Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy

Source: Clinical Cancer Research Authors: Peter H. O'Donnell and M. Eileen Dolan A long-term goal of pharmacogenomics research is the design of individualized therapy based on the genomic sequence of the patient, in order to maximize response and minimize adverse drug reactions. Pharmacoethnicity, or ethnic diversity in drug response or toxicity, is becoming increasingly recognized as an important factor accounting for interindividual variation in anticancer drug responsiveness. Although pharmacoethnicity is determined by genetic and nongenetic factors, there is rapidly accumulating clinical evidence about ethnic differences in the frequencies of polymorphisms within many of the important cancer drug-related genes. This article reviews the current clinical evidence for ethnic differences in anticancer drug dispositionand sensitivity while highlighting the challenges, and potential solutions, to acquiring such knowledge. The discovery of "ethnic-specific genetic signatures," representing unique sets of drug susceptibility-governing polymorphisms, may be the outcome of such work. Ultimately, such understanding will further the lofty goal of individualization of chemotherapy based on a person's unique genetic make-up to improve the tolerability and effectiveness of chemotherapy for all patients.

2009-07-30T19:13:03-07:00July, 2009|Oral Cancer News|

Fighting malnutrition in cancer patients

Source: MSNBC Author: Staff Poor nutrition contributes to 1 in 5 cancer deaths; experts urge counseling WASHINGTON - The statistic is shocking: Severe malnutrition and weight loss play a role in at least one in five cancer deaths. Yet nutrition too often is an afterthought until someone's already in trouble. A move is on to change that, from hospitals that hire fancy gourmet chefs to the American Cancer Society's dietitians-on-call phone service. With cancer, you've got to "bring a lot more nutrients to each spoonful of food," Certified Master Chef Jack Shoop is learning. A former restaurateur, he's newly in charge of the kitchen at the Cancer Treatment Centers of America in Philadelphia. Don't underestimate the added temptation should the result resemble Bon Appetit: "The visual hardiness, and the actual heartiness, of these foods has to be understood for them to embrace it," Shoop insists. Tempting the palate is a huge hurdle: At diagnosis, up to a quarter of patients already have their appetite sapped, and most treatments can bring side effects that worsen the problem. Aside from the well-known nausea, vomiting and diarrhea, some cancers inhibit absorption of the nutrients patients force down. Not to mention strangely altered taste, mouth sores, dry mouth, difficulty swallowing and constipation. Literally wasting away About half of all cancer patients eventually suffer serious weight loss and malnutrition, a wasting syndrome called cachexia where they don't just lose excess fat but vital muscle. A healthy person's body adjusts when it doesn't get enough calories, [...]

2009-07-10T11:17:09-07:00July, 2009|Oral Cancer News|

U.S. scientists say Lilly Erbitux cancer drug not worth price

Source: Bloomberg Author: Lisa Rapaport Eli Lilly & Co.’s tumor-fighter Erbitux doesn’t prolong lung cancer patients’ lives enough to justify its $80,000 cost, U.S. scientists said in commentary published today. Erbitux added to other cancer drugs extends survival about 1.2 months more than chemotherapy alone, making the price too high for a “marginal benefit,” commentary in the Journal of the National Cancer Institute said. Erbitux, which Lilly markets with Bristol-Myers Squibb Co., generated $1.3 billion last year as treatment approved for other malignancies. The high price of some of the newest cancer medicines are coming under scrutiny as part of an effort by lawmakers and health officials to rein in overall medical costs. President Barack Obama has set aside $1.1 billion in the U.S. economic stimulus bill to study the comparative effectiveness of treatments for cancer and other diseases. “We must avoid the temptation to tell a patient that a new drug is available if there is little evidence that it will work better than established drugs that could be offered at a miniscule fraction of the cost,” wrote the commentators, Tito Fojo with the National Cancer Institute and Christine Grady at the National Institutes of Health. Lilly, of Indianapolis, and marketing partner Bristol- Myers, of New York, withdrew an application to extend the Erbitux’s use to lung tumors in February after the Food and Drug Administration questioned differences in American and European versions of the treatment. $10,000 a Month The authors projected that Erbitux costs $80,000 based on a typical course of treatment for lung [...]

2009-06-30T16:01:21-07:00June, 2009|Oral Cancer News|

Diet, nutrition, and cancer — don’t trust any single study

Source: American Association for Cancer Research (AACR) 100th Annual Meeting Author: Zosia Chustecka Numerous studies on diet and cancer were presented here at the American Association for Cancer Research (AACR) 100th Annual Meeting, but several of the findings that were highlighted in AACR press releases — and thus are likely to be picked up by the lay media — run counter to the accumulated body of evidence, and some of the comments based on these studies are untrue or premature. So said Walter Willet, MD, DrPH, from the department of nutrition at Harvard School of Public Health, in Boston, Massachusetts, in an exclusive interview with Medscape Oncology. "No conclusions should be made on the basis of a single study," he said. Dr. Willett presented an overview entitled "Diet, Nutrition, and Cancer: The Search for Truth," in which he reviewed many of the associations that have been suggested by epidemiologic studies. These include consumption of red meat, meat cooked at a high temperature, a high-fat diet, and alcohol all increasing the risk, and fruit and vegetables decreasing the risk. However, much of the evidence for these links is rather weak, he said; the most robust evidence supports a link between obesity and an increased risk for cancer. "The estimate that diet contributes to around 30% to 35% of cancers is still reasonable," Dr. Willet said, "but much of this is related to being overweight and inactive." "At this point in time, being overweight is second only to smoking as a clear [...]

Calcium intake may protect against cancer

Source: Author: Laurie Barclay, MD & Hien T. Nghiem, MD Calcium intake may protect against cancer, particularly gastrointestinal tract cancer, according to the results of a prospective study reported in the February 23 issue of the Archives of Internal Medicine. "Dairy food and calcium intakes have been hypothesized to play roles that differ among individual cancer sites, but the evidence has been limited and inconsistent," write Yikyung Park, ScD, from the National Cancer Institute in Bethesda, Maryland, and colleagues. "Moreover, their effect on cancer in total is unclear." In the National Institutes of Health-AARP (formerly known as the American Association of Retired Persons) Diet and Health Study, the investigators evaluated the association of dairy food and calcium intakes with incidence of total cancer and cancer at individual sites. A food frequency questionnaire was used to determine intakes of dairy food and calcium from foods and supplements. Linkage with state cancer registries allowed identification of incident cancer cases. Relative risks and 2-sided 95% confidence intervals (CIs) were determined with a Cox proportional hazard model. During follow-up (average, 7 years), 36,965 cancer cases were identified in men and 16,605 in women. In men, calcium intake was not associated with total cancer. However, calcium intake was nonlinearly associated with total cancer in women, with the risk decreasing up to approximately 1300 mg/day but with no further risk reduction above those levels. Dairy food and calcium intakes were inversely associated with cancers of the digestive system in both men and women. Multivariate relative risk [...]

Cancer to be world’s top killer by 2010, WHO says

Source: news.myway.com Author: Mike Stobbe Cancer will overtake heart disease as the world's top killer by 2010, part of a trend that should more than double global cancer cases and deaths by 2030, international health experts said in a report released Tuesday. Rising tobacco use in developing countries is believed to be a huge reason for the shift, particularly in China and India, where 40 percent of the world's smokers now live. So is better diagnosing of cancer, along with the downward trend in infectious diseases that used to be the world's leading killers. Cancer diagnoses around the world have steadily been rising and are expected to hit 12 million this year. Global cancer deaths are expected to reach 7 million, according to the new report by the World Health Organization. An annual rise of 1 percent in cases and deaths is expected - with even larger increases in China, Russia and India. That means new cancer cases will likely mushroom to 27 million annually by 2030, with deaths hitting 17 million. Underlying all this is an expected expansion of the world's population - there will be more people around to get cancer. By 2030, there could be 75 million people living with cancer around the world, a number that many health care systems are not equipped to handle. "This is going to present an amazing problem at every level in every society worldwide," said Peter Boyle, director of the WHO's International Agency for Research on Cancer. Boyle spoke at [...]

2008-12-09T12:05:31-07:00December, 2008|Oral Cancer News|
Go to Top